Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
$1.88
+2.7%
$2.54
$1.79
$8.94
$33.49MN/A400,627 shs193,914 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.72
+1.8%
$1.30
$0.47
$4.25
$8.75M1.41429,008 shs49,236 shs
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
$2.75
+2.2%
$2.46
$1.70
$20.00
$37.21M0.43123,878 shs20,763 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$1.65
+20.4%
$0.71
$0.24
$3.98
$54.77M0.741.53 million shs1.12 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
0.00%-3.09%-13.76%-31.88%+187,999,900.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%-5.49%+95.90%+84.97%+826.23%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
0.00%0.00%+36.82%-4.51%+274,999,900.00%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
0.00%+47.32%+174.13%+97.63%-35.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
$1.88
+2.7%
$2.54
$1.79
$8.94
$33.49MN/A400,627 shs193,914 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.72
+1.8%
$1.30
$0.47
$4.25
$8.75M1.41429,008 shs49,236 shs
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
$2.75
+2.2%
$2.46
$1.70
$20.00
$37.21M0.43123,878 shs20,763 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$1.65
+20.4%
$0.71
$0.24
$3.98
$54.77M0.741.53 million shs1.12 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
0.00%-3.09%-13.76%-31.88%+187,999,900.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%-5.49%+95.90%+84.97%+826.23%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
0.00%0.00%+36.82%-4.51%+274,999,900.00%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
0.00%+47.32%+174.13%+97.63%-35.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
3.50
Strong Buy$23.501,150.00% Upside
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2.00
HoldN/AN/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
3.14
Buy$32.331,075.76% Upside
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00203.03% Upside

Current Analyst Ratings Breakdown

Latest MTNB, RLMD, OKUR, and MDCX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
8/26/2025
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$34.00
8/22/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
8/13/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
8/13/2025
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
7/9/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
7/1/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
6/23/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
6/9/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/AN/AN/AN/A$0.29 per shareN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/A$4.43 per shareN/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/A$7.78 per shareN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.18 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$11.16M-$1.34N/AN/AN/AN/A-549.30%-228.06%N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$22.94M-$3.89N/AN/AN/A-123.06%-94.28%N/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-$52.67M-$4.80N/AN/AN/AN/A-60.52%-55.43%11/6/2025 (Estimated)
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)

Latest MTNB, RLMD, OKUR, and MDCX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-$1.23-$1.14+$0.09-$1.14N/AN/A
8/11/2025Q2 2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$0.39-$0.43-$0.04-$0.43N/AN/A
8/7/2025Q2 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.25-$0.30-$0.05-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A
1.29
1.29
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
5.53
5.53
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/A
11.13
11.13
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
4.11
4.11

Institutional Ownership

CompanyInstitutional Ownership
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
90.98%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%

Insider Ownership

CompanyInsider Ownership
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
11.20%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
2.30%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
20.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A17.82 million15.82 millionN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
305.09 million4.60 millionN/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/A13.53 million13.22 millionN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million26.32 millionOptionable

Recent News About These Companies

Relmada Therapeutics (NASDAQ:RLMD) Stock Price Up 44.5% - Still a Buy?
Relmada Therapeutics Reports Promising Phase 2 Study Results
RLMD Relmada Therapeutics, Inc. - Seeking Alpha
Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Medicus Pharma stock logo

Medicus Pharma NASDAQ:MDCX

$1.88 +0.05 (+2.73%)
As of 09/5/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Matinas Biopharma stock logo

Matinas Biopharma NYSE:MTNB

$1.72 +0.03 (+1.78%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.67 -0.05 (-2.91%)
As of 09/5/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

OnKure Therapeutics stock logo

OnKure Therapeutics NASDAQ:OKUR

$2.75 +0.06 (+2.23%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.74 -0.01 (-0.36%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$1.65 +0.28 (+20.44%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.64 -0.01 (-0.67%)
As of 09/5/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.